GH — what changed in the latest 10-Q
A section-by-section comparison of GH's newest periodic SEC filing (10-K/10-Q) against the prior same-form filing: paragraphs added and removed per section, with verbatim excerpts. Purely a deterministic text diff — no similarity scores, no directional read, not investment advice.
Comparing 10-Q · 2026-11-05 vs the prior 10-Q · 2026-07-30
| Section | Outcome | Added | Removed | Minor | Unchanged |
|---|---|---|---|---|---|
| MD&A | Text added/removed | +27 | −29 | ~15 | 31 |
| Market risk (Item 3) | Text added/removed | 0 | 0 | ~2 | 1 |
| Controls & procedures | Text added/removed | 0 | 0 | ~1 | 2 |
| Legal proceedings | No paragraph-level changes | 0 | 0 | 0 | 1 |
| Risk factors | Some risk factors updated | +7 | 0 | ~1 | 1 |
| Other information | Text added/removed | 0 | 0 | ~2 | 3 |
Counts are paragraphs; added/removed means text added or removed vs the prior filing — no direction or judgement implied.
Representative excerpts
Up to 5 excerpts of about 300 characters per section, quoted verbatim from the two SEC filings.
MD&A
Text added vs the prior filing · source: 10-Q · 2026-11-05
General and administrative expense. Our general and administrative expenses include costs for our executive, accounting and finance, information technology, legal and human resources functions. These expenses consist principally of salaries, bonuses, employee benefits, travel expenses and stock-base…
Comparison of the Three Months Ended September 30, 2026 and 2025
Total revenue was $361.0 million for the three months ended September 30, 2026, compared to $265.2 million for the three months ended September 30, 2025, an increase of $95.8 million, or 36%.
Oncology revenue was $231.3 million for the three months ended September 30, 2026, compared to $184.4 million for the three months ended September 30, 2025, an increase of $46.9 million, or 25%. This increase was driven primarily by an increase in oncology test volume to approximately 117,000 for th…
Biopharma and data revenue was $59.0 million for the three months ended September 30, 2026, compared to $54.7 million for the three months ended September 30, 2025, an increase of $4.2 million, or 8%. This increase was driven primarily by an increase in volume of our GuardantINFINITY test.
Text removed vs the prior filing · source: 10-Q · 2026-07-30
We generated total revenue of $335.0 million and $232.1 million for the three months ended June 30, 2026, and 2025, respectively, and $636.6 million and $435.6 million for the six months ended June 30, 2026, and 2025, respectively. We also incurred net losses of $120.1 million and $99.9 million for …
While each of these areas presents significant opportunities for us, they also pose significant risks and challenges that we must address. See Part I, Item 1A, “Risk Factors” of our Annual Report on Form 10-K for the year ended December 31, 2025, and Part II, Item 1A, “Risk Factors” of this Quarterl…
reimbursement for our Guardant360 CDx, Guardant360 Liquid, Guardant360 Liquid CDx, Guardant360 Tissue, and Guardant Reveal tests performed for qualifying patients.
General and administrative expense. Our general and administrative expenses include costs for our executive, accounting and finance, information technology, legal and human resources functions. These expenses consist principally of salaries, bonuses, employee benefits, travel expenses and stock-base…
expenses. In addition, our general and administrative expenses also include severance costs related to workforce reduction. We expect that our general and administrative expenses will continue to increase as we incur additional costs to support the growth of our business. These expenses, though expe…
Risk factors
Text added vs the prior filing · source: 10-Q · 2026-11-05
During the third quarter of fiscal 2026, there were no material changes to our previously disclosed risk factors, other than the following:
Cybersecurity incidents, including attacks facilitated by artificial intelligence, as well as those of our third-party service providers, could compromise sensitive information related to our business, prevent us from accessing it and expose us to substantial liability, which could adversely affect …
We depend on information technology systems for significant elements of our operations, including our laboratory information management system, our computational biology system, our knowledge management system, our customer reporting and our GuardantConnect software platform. Our information technol…
AI may enable malicious actors to automate attacks, increase their speed, scale and sophistication, and exploit previously unknown or unremediated system vulnerabilities. We expect the use of AI to identify, and potentially exploit, vulnerabilities in information technology systems to become more pr…
We and certain of our service providers are from time to time subject to cybersecurity incidents. For example, we recently learned of unauthorized access to our electronic ordering portal, which some physicians use to place test orders, receive and look up results, and other customer facing interfac…
How to read Risk Factors (Item 1A) in a 10-Q
A 10-Q risk-factor section usually takes one of three forms; this page classifies it as one of:
- Pointer — the filer states there have been no material changes and points back to the annual 10-K risk factors; there is no own risk text to compare this quarter.
- Partial update — the filer carves out specific updated risks ("except as set forth below"); the excerpts show exactly what is new this quarter.
- Restated in full — the quarter carries the complete risk-factor text. When the prior quarter was only a pointer there is no prior full text to diff against, so the page flags the section as restated instead.
This describes the filing structure only — it is never a judgement on whether risk went up or down.
Source: text-level diff of the two SEC EDGAR filings · deterministic (no AI-generated content) · for reference only · not investment advice